New results from a study of a drug called Gazyva (obinutuzumab) showed that it significantly reduced disease activity in adults with systemic lupus erythematosus (SLE).

Kyndryl (KD) shares were active in extended trading on Tuesday after the IT infrastructure company posted second-quarter ...

UCB has scored an FDA approval for ultra-rare disease treatment Kygevvi, continuing the positive momentum for the Belgian ...

Dybala was forced to leave the field immediately, and a few days later, tests diagnosed a lesion of the rectus femoris. Yet ...

Harmony also touts late-stage asset EPX-100 (clemizole hydrochloride), which the biotech is running through a pair of phase 3 trials in Dravet syndrome and Lennox-Gastaut Syndrome— both rare forms of ...

Kyle Kennedy was experiencing pain and swelling in his neck but doctors told him he had swollen glands and to take ...

Kymera Therapeutics, Inc. ( ($KYMR) ) has released its Q3 earnings. Here is a breakdown of the information Kymera Therapeutics, Inc. presented to ...

Discover Kymera Therapeutics' Q3 2025 earnings, clinical trial milestones in immunology, and strategic Gilead partnership.

Kymera Therapeutics, Inc. (($KYMR)) has held its Q3 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...